On next-gen GLP-1 drugs. “A mere decade ago, obesity drugs powerful enough…
On next-gen GLP-1 drugs. “A mere decade ago, obesity drugs powerful enough for people to routinely drop double-digit percentages of their body weight were unheard-of. Today, there are two, and they feel ubiquitous.” 💬 Join the discussion on kottke.org →
Lilly slightly lowers self-pay prices for single-dose vials of Zepbound
Eli Lilly will shave $50 off the self-pay price for most single-dose vials of its blockbuster weight loss drug Zepbound, about a month after agreeing to lower the prices for its multi-dose pens as part …
Popular fat jab could slow Alzheimer’s by slashing brain shrinkage and boosting memory
A FAT jab could help slow down Alzheimer’s by slashing brain shrinkage, according to a small British study. Liraglutide, the GLP-1 drug already used to manage type 2 diabetes, has sparked fresh hope that weight-loss injections could protect the brain. It comes just days after semaglutide, the ingredient in blockbuster jab Wegovy, was found not to…
Why the Marks & Spencer share price fell 14% in November
November proved to be a tough month for the Marks & Spencer (LSE:MKS) share price. It was one of the worst-performing stocks in the FTSE 100, falling almost 14% in the month. Here’s what caused the move and where I think it could go from here. Key factors to note In April 2025, the business […]
Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes
This systematic review and meta-analysis assesses the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity, prediabetes, or type 2 diabetes.
FATP2 at the crossroads of fatty acid transport, lipotoxicity, and complex disease
Type 2 diabetes mellitus affects over 38 million Americans, with diabetic kidney disease as a major complication partly driven by lipotoxicity. Fatty acid transport protein 2 (FATP2) regulates uptake and activation of long-chain fatty acids, making it a therapeutic target in metabolic disease. In this issue of the JCI, Khan et al. investigated FATP2 in […]
Fatty acid transport protein 2 inhibition enhances glucose tolerance through α cell–mediated GLP-1 secretion
Type 2 diabetes affects more than 38 million people in the United States, and a major complication is kidney disease. During the analysis of lipotoxicity in diabetic kidney disease, global fatty acid transport protein 2 (FATP2) gene deletion was noted to markedly reduce plasma glucose in db/db mice due to sustained insulin secretion. To identify […]
Coprescribing GLP-1 Receptor Agonists and Lifestyle
To the Editor The importance of integrating lifestyle modification when initiating glucagon-like peptide-1 and dual receptor agonists (GLP-1 RAs) for type 2 diabetes and/or obesity cannot be overstated. As referral to a registered dietitian or lifestyle medicine specialist is ideal but not always feasible, providing clinicians with practical, evidence-based resources for use when coprescribing GLP-1 […]
Home hospital care demonstrates success in rural communities
One in five people in the United States live in a rural area. Patients in rural communities often struggle to access care because of travel difficulties, high costs and limited resources, leading to worse medical outcomes. With over 150 rural hospital closures since 2010, innovative approaches to care delivery in rural areas are needed.
Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program
Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug purchased through LillyDirect. Both pharmas recently struck a deal with the White House for cheaper prices via the yet-to-be-launched TrumpRx.